Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | POLB | P06746 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15503221 | 0.92 | POLB (0.50) | ALDH1A1POLBTDP1APEX1SMN1; SMN2 | |
| SCHEMBL47606 | 0.79 | FPR3 (0.36) | ALDH1A1KDM4E | |
| SCHEMBL47619 | 0.79 | FPR3 (0.36) | ALDH1A1KDM4E | |
| SCHEMBL15503178 | 0.79 | POLB (0.68) | ALDH1A1POLBTDP1APEX1SMN1; SMN2 | |
| SCHEMBL18735712 | 0.76 | ALDH1A1 (0.43) | ALDH1A1POLBTDP1APEX1MEN1 | |
| SCHEMBL18735634 | 0.76 | ALDH1A1 (0.43) | ALDH1A1POLBTDP1APEX1MEN1 | |
| SCHEMBL24120969 | 0.72 | TDP1 (0.46) | ALDH1A1POLBTDP1APEX1SMN1; SMN2 | |
| SCHEMBL13331898 | 0.72 | POLB (0.32) | ALDH1A1POLBTDP1HBBHSD17B10 | |
| SCHEMBL14495731 | 0.72 | TDP1 (0.46) | ALDH1A1POLBTDP1APEX1SMN1; SMN2 | |
| SCHEMBL23612575 | 0.72 | TDP1 (0.46) | ALDH1A1POLBTDP1APEX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371579-A1 | VEGETABLE OIL-DERIVED EPOXY COMPOSITIONS HAVING IMPROVED PERFORMANCE | WASHINGTON STATE UNIVERSITY | 2021-12-02 | — | — | US | disclosed |
| US-20210252159-A1 | CONJUGATES OF CARTILAGE-HOMING PEPTIDES | FRED HUTCHINSON CANCER CENTER | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252159-A1 | CONJUGATES OF CARTILAGE-HOMING PEPTIDES | CD44, MATR3, CCL2 | ALDH1A1 2621/4885POLB 4029/4885TDP1 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.